ArticleFrontiers in microbiology2026
Multi-feature fusion for gene prediction and functional peptide identification.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticancer peptides (ACPs) have demonstrated potent antitumor activity and low toxicity, offering considerable potential in cancer therapeutics. Meanwhile, antimicrobial peptides (AMPs)serve as key components of the innate immune defense system. Owing to their broad-spectrum antimicrobial activity and low propensity for inducing resistance, AMPs have attracted considerable attention in the fields of infection control and immunotherapy. Accurate identification of ACPs and AMPs is critical for the discovery of novel therapeutic agents. However, wet-lab identification is often time-consuming, costly, and inefficient, falling short of the demands for highthroughput drug screening. Furthermore, existing computational methods exhibit limitations in feature representation and cross-task prediction capability. To address these challenges, a tool for functional peptide prediction is proposed, namely GP2FI, which consists of two sequential stages: a gene prediction model (MHA-preconv) and a functional peptide identification model (FuncPred-CB). MHA-preconv integrates CNNs with Transformer encoder layers to form a two-stage deep architecture, effectively capturing both local sequence patterns and long-range dependencies. Based on the coding regions identified by MHA-preconv, FuncPred-CB incorporates a pre-trained BERT language model to automatically extract contextual semantic features from amino acid sequences. Experimental results on multiple benchmark datasets demonstrate that MHA-preconv and GP2FI consistently outperforms the state-of-the-art methods in terms of accuracy and other performance metrics.The code for the GP2FI can be found at https://github.com/ma999-mxl/maLBX.git.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.